Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis

NCT01093326 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

353

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Ponesimod 10 mg
DRUG: Ponesimod 20 mg
DRUG: Ponesimod 40 mg

Sponsor

Actelion